RSS Feed

Bonseyes success story

Euresearch has just published a Success Story about the Horizon 2020 Project Bonseyes.

Artificial intelligence is projected to add over €13 trillion to the global economy by 2030 but European companies risk being shut out by the ‘data wall’ dominated by such internet giants as Google.

Bonseyes (Platform for Open Development of Systems of Artificial Intelligence) aims to get over the wall using the new power of edge computing and by leveraging Europe’s leadership in embedded systems.

SCIPROM is glad to be part of Bonseyes, supporting the project in terms of management, communication and dissemination since its proposal stage.

H2020 Work Programme 2018-2020 launched today!

The Work Programme 2018-2020 of Horizon 2020 was launched by the European Commission today.

Horizon 2020 is the largest multinational programme dedicated to research & innovation and it is "open to the world". This means that researchers, universities, research organisations, companies and non-governmental organisations from across the globe can apply to participate in the activities of the Work Programme carried out mainly through calls  for proposals.

For your information and further dissemination, please check the EC Press Release.

If you are interested to apply, consult the Horizon 2020 participant portal. The detailed topic descriptions, call conditions and budget information for any of these calls can be found there.

If you have any questions regarding the 2018 calls or if you are looking for support in view of submitting a Horizon2020 project in 2018, do not hesitate to contact us. SCIPROM will be happy to support you from your first idea to the final project report and be on your side all along the project duration.

Sources: EC, Euresearch

Now open: ERC Consolidator Grants Call 2018

ERC Consolidator Grants are designed to support excellent Principal Investigators at the career stage at which they are consolidating their own independent research team.

Up to €2 mio are available for projects of up to 5 years duration.

The call closes on 15 February 2018.

The mandatory templates are available from the Participant Portal once having registered for the call.

For more information, please consult the ERC website. 

Sources: Euresearch, ERC

Draft H2020 Work Programmes 2018-2020

The European Commission is currently making public the draft work programmes 2018-2020 for most of the thematic programmes in Horizon 2020. These drafts are available before their adoption to provide potential participants with the currently expected main lines of the work programmes. The remaining drafts are expected to be released this week.

Please note that they are still in a DRAFT version and as such have not been adopted or endorsed by the European Commission. Any views expressed are the views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission.

The adoption of the work programme will be announced on the Horizon 2020 website and on the Participant Portal towards end of October 2017. Only the adopted work programmes will have legal value. Information and topic descriptions indicated in these drafts may not appear in the final work programme; and likewise, new elements may be introduced at a later stage.

More information and links to the draft work programmes can be found on the EC website.  

Sources: EC, Euresearch

Innovative Medicines Initiative (IMI): evaluations of IMI1 and IMI2

The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.

The experts conclude that IMI programme ‘remains relevant and justified’ and that ‘positive contributions on the drug development process have been realised’. Positive points recognised in the reports include:

- the IMI role in the creation of collaborative research networks that have enhanced trust between partners from different sectors, and triggered a mind shift as partners came to understand each other’s needs;
- the quality of the research emerging from IMI projects;
- the creation of important resources and tools for drug development, some of which are already being used by researchers in their daily work.

The reports also note that 90% of the people who responded to the online survey agreed that the EU should cooperate with industry in the context of a public-private partnership on health.

Suggestions for improvement concern performance indicators, increasing the involvement of SMEs as well as dissemination and communication of the projects' results.

Read the European Commission's press release on the evaluation
Read the new IMI brochure on results and impacts

Source: IMI

Swiss wins 2017 Nobel Prize in chemistry

Jacques Dubochet of Switzerland's University of Lausanne has been awarded this year’s Nobel prize in chemistry together with two other scientists from Britain and the United States.

Announcing the winners on Wednesday, the Royal Swedish Academy of Sciences said the three scientists helped develop cryo-electron microscopy - a method to have detailed images of life’s complex machineries in atomic resolution.

Dubochet, born in 1942, is a honorary professor of biophysics at Lausanne University and worked at Basel and Geneva Universities.

Innovative Medicines Initiative (IMI) 2 Call 13: Indicative Topics Published

IMI 2 has just published a list of indicative topics for the call 13 which is foreseen to be launched before the end of the year.

The following topics are under consideration for inclusion in future IMI calls for proposals:

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- CONCEPTION - continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Federated and privacy-preserving machine learning in support of drug discovery
- Pilot programme on a clinical compound bank for repurposing. This programme includes the following topics: Cardiovascular diseases and diabetes, Respiratory diseases, Neurodegenerative diseases and Rare/orphan diseases

Source: IMI2

Evolution of the European framework programme

The European Parliament released an in-depth analysis on the advancement of and key data from FP1 to Horizon 2020 in view of FP9.

This paper aims to provide an overview of the evolution of the EU framework programme for research and innovation. The paper focuses on the evolution of the legal basis to adopt the programme, its structure and its budget. It then highlights key issues that will have to be addressed in the coming years in the discussion leading to the adoption of the ninth framework programme.

10 years ERC, 10 portraits

In 10 years, The European research council ERC has funded more than 1000 researchers across Europe. Discover here some of them. 

First Swiss start-ups receive financial support from Horizon 2020 SME instrument

Four Swiss start-ups will receive CHF 50’000 each through the Horizon 2020 SME instrument scheme. The instrument, provided with about € 3 billion, is accessible to Swiss SMEs since January 2017. Next application deadline is 6 September.

Since January 2017, Swiss researchers and organisations are able to fully participate in Horizon 2020, the European Union's research and innovation funding programme. Since then Swiss SME including start-ups are eligible to apply for the Horizon 2020 SME instrument. Provided with about € 3 billion in funding over the period 2014-2020, the SME Instrument helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.

This week the first Swiss companies were announced which were selected for funding through the SME instrument. These include:

AMPHIRO (Cleantech): connected shower consumption meters

Daedalean (ICT): autonomous flight control for the electric personal aircraft of the near future

DEPsys (Cleantech): smart grid optimisation platform

SENSARS NEUROPROSTHETICS (Medtech): neuroprosthetic device allowing amputees to feel again from missing limbs

Each project will receive €50’000 to finance a feasibility study for innovative products that can disrupt the market. Companies also receive business support services and up to three days of free business coaching.

These companies were selected for a Phase 1 project and may in future apply for a Phase 2 financing scheme, allowing to benefit from a further financing - up to €2.5M - for activities focusing on bringing innovative ideas (product, process, service etc.) to industrial readiness and maturity for market introduction, focusing on demonstration, testing, prototyping, piloting, scaling-up, miniaturization, design, market replication and the like.

SCIPROM will be pleased to support Swiss SMEs in the preparation of proposals for the SME instrument, together with our business partner Inspiralia, a Spanish company which has long-term experience in the SME instrument and supported DEPsys in their SME instrument proposal prepation. 

See Older Posts...